These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Linac-based stereotactic salvage reirradiation for intraprostatic prostate cancer recurrence: toxicity and outcomes. Cozzi S; Finocchi Ghersi S; Bardoscia L; Najafi M; Blandino G; Alì E; Augugliaro M; Vigo F; Ruggieri MP; Cardano R; Giaccherini L; Iori F; Botti A; Trojani V; Ciammella P; Iotti C Strahlenther Onkol; 2023 Jun; 199(6):554-564. PubMed ID: 36732443 [TBL] [Abstract][Full Text] [Related]
3. Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT). Jereczek-Fossa BA; Rojas DP; Zerini D; Fodor C; Viola A; Fanetti G; Volpe S; Luraschi R; Bazani A; Rondi E; Cattani F; Vavassori A; Garibaldi C; Alessi S; Pricolo P; Petralia G; Cozzi G; De Cobelli O; Musi G; Orecchia R; Marvaso G; Ciardo D Br J Radiol; 2019 Feb; 92(1094):20180494. PubMed ID: 30379566 [TBL] [Abstract][Full Text] [Related]
4. Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer. Bergamin S; Eade T; Kneebone A; Booth J; Hsiao E; Schembri GP; Szymura K; Le A; Kwong C; Brown C; Hunter J; Hruby G Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1172-1178. PubMed ID: 32659332 [TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial. Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579 [TBL] [Abstract][Full Text] [Related]
6. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results. Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510 [TBL] [Abstract][Full Text] [Related]
7. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT). Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738 [TBL] [Abstract][Full Text] [Related]
8. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial. Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270 [TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity. Ugurluer G; Atalar B; Zoto Mustafayev T; Gungor G; Aydin G; Sengoz M; Abacioglu U; Tuna MB; Kural AR; Ozyar E Br J Radiol; 2021 Jan; 94(1117):20200696. PubMed ID: 33095670 [TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes of Prostate SBRT Using Non-adaptive MR-Guided Radiotherapy. Sandoval ML; Rishi A; Latifi K; Grass GD; Torres-Roca J; Rosenberg SA; Yamoah K; Johnstone PAS Cancer Control; 2024; 31():10732748241270595. PubMed ID: 39206515 [TBL] [Abstract][Full Text] [Related]
11. Dosimetric predictors for genitourinary toxicity in MR-guided stereotactic body radiation therapy (SBRT): Substructure with fraction-wise analysis. Pham J; Neilsen BK; Liu H; Cao M; Yang Y; Sheng K; Ma TM; Kishan AU; Ruan D Med Phys; 2024 Jan; 51(1):612-621. PubMed ID: 38055353 [TBL] [Abstract][Full Text] [Related]
12. Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy. D'Agostino GR; Di Brina L; Mancosu P; Franzese C; Iftode C; Franceschini D; Clerici E; Tozzi A; Navarria P; Scorsetti M Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):614-621. PubMed ID: 30825495 [TBL] [Abstract][Full Text] [Related]
13. A Prospective Study of Stereotactic Body Radiotherapy (SBRT) with Concomitant Whole-Pelvic Radiotherapy (WPRT) for High-Risk Localized Prostate Cancer Patients Using 1.5 Tesla Magnetic Resonance Guidance: The Preliminary Clinical Outcome. Poon DMC; Yuan J; Yang B; Wong OL; Chiu ST; Chiu G; Cheung KY; Yu SK; Yung RWH Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884553 [TBL] [Abstract][Full Text] [Related]
14. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy. Mbeutcha A; Chauveinc L; Bondiau PY; Chand ME; Durand M; Chevallier D; Amiel J; Kee DL; Hannoun-Lévi JM Radiat Oncol; 2017 Mar; 12(1):49. PubMed ID: 28274241 [TBL] [Abstract][Full Text] [Related]